Designer SARS-CoV-2 RBD vaccine produces dramatically improved antibody response in preclinical trials The importance of computational modeling in the prediction of the course of the ongoing coronavirus disease 2019 (COVID-19) pandemic, as well as evaluating multiple potential drug leads, has never been more clear. Now, a new study describes a set of designer vaccine antigens that may improve vaccine stability as well as enhance the neutralizing antibody response. The virus causing this pandemic is the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes an asymptomatic or mild infection in the vast majority, but spreads rapidly and extensively to produce a huge caseload in a relatively short period of time. This has led to overwhelming demands on healthcare services in many severely affected countries.